Клинические, лабораторные и молекулярно-генетические маркеры прогрессии неалкогольной жирной болезни печени (обзор литературы и собственные данные)

Аннотация

Калит сўзлар: Alkogolsiz jigar yog'li kasalligi (NAFLD) gepatologiyada eng Alkogolsiz yog'li jigar keng tarqalgan kasalliklardan biridir. Avvalo, bu alkogolsiz kasalligi steatohepatit (NASH), jigar etishmovchiligi va gepatosellular Alkogolsiz steatohepatit karsinomaning rivojlanishi bilan NAFLD rivojlanishining yuqori Sitokinlar MBOAT7 geni xavfi bilan bog'liq. Epidemiologik va genetik tadqiqotlar 1 Tashkent medical Academy. Bukhara state medical institute, Bukhara, Uzbekistan 2 Tashkent medical Academy. Bukhara state medical institute, Bukhara, Uzbekistan Жамият ва инновациялар – Общество и инновации – Society and innovations Special Issue – 2 (2021) / ISSN 2181-1415 GCKR geni NAFLDning morfologik bosqichi va irsiy omillar o'rtasidagi Siroz bog'liqlikni ko'rsatdi. Maqolada sitokinlar, MBOAT7 va GCKR Lipidlar genlari haqidagi adabiyotlar ko'rib chiqilgan. Shuningdek, Semirish MBOAT7 va GCKR genlarining bir varianti NAFLD va yuqori qon zardobida triglitseridlar darajasi yuqori bo'lgan bemorlarda fibroziya xavfi yuqori. Клинические, лабораторные и молекулярно-генетические маркеры прогрессии неалкогольной жировой болезни печени (обзор литературы и собственные данные) АННОТАЦИЯ Ключевые слова: Неалкогольная жировая болезнь печени (НАЖБП) - одно Неалкогольная жировая из самых распространенных заболеваний в гепатологии. болезнь печени Прежде всего, это связано с высоким риском Неалкогольный прогрессирования НАЖБП с развитием неалкогольного стеатогепатит Цитокины стеатогепатита (НАСГ), печеночной недостаточности и Ген MBOAT7 гепатоцеллюлярной карциномы. Эпидемиологические и Ген GCKR генетические исследования показали взаимосвязь между Цирроз морфологической стадией НАЖБП и наследственными Липиды факторами. В статье представлен обзор литературы по Ожирение цитокинам, генам MBOAT7 и GCKR. Кроме того, вариант гена MBOAT7 и GCKR связан с высоким риском фиброза у пациентов с НАЖБП и повышенными уровнями триглицеридов в сыворотке. THE URGENCY OF THE PROBLEM Today, non-alcoholic fatty liver disease (NAFLD) attracts the attention of a wide range of specialists both in our country and abroad. Currently, non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases in hepatology, leading to a deterioration in the quality of life, disability and death. The overall prevalence of NAFLD in the population ranges from 10 to 40% [3,5,9,19,38]. Non-alcoholic fatty liver disease is not related to alcohol consumption, a chronic disease characterized by the accumulation of fat in liver cell and that plays an important role in diseases of the gastrointestinal tract [3,11]. Thus type of NAFLD may be, as independent disease, combined with obesity, 2nd type of diabetes mellitus and dyslipidemia, and according to a several authors, secondary functional violations of liver, for instance, with dyslipidemia, they can manifest as a NAFLD. In the early stages of the NAFLD are characterized by ineffectiveness of specific treatment and progressive progression of the disease due to the nonspecific clinical signs [3,25,27]. NAFLD - progressive, chronic multifactorial steatosis of liver – (accumulation of fat in the liver, fatty dystrophy of hepatocytes), steatohepatitis – formation of inflammatory infiltrate around the site of necrosis in hepatocytes, non-alcoholic fibrosis-cirrhosis: destruction of liver architectonics and the disease complicated by connective tissue growth, that has been the main focus of local and foreign hepatologists for the last 10 years [3,15,34]. 400 Жамият ва инновациялар – Общество и инновации – Society and innovations Special Issue – 2 (2021) / ISSN 2181-1415 When the disease is periodic in 12-40% patients after 8-13 years may convert to non-alcohol steatohepatitis, from that in 15% patients may be liver cirrhosis and liver failure. After 10 years liver cirrhosis may convert to hepatocellular carcinoma in 7 % patients. NAFLD - the facts in last 10 years confirm growth of disease [26,35,37]. NAFLD is widespread in western Europe and USA. The spreading in common population of NAFLD L is not learnt well, but some authors determined that occurs 3-58% in Italy and USA [9,35]. The growth rate of NAFLD is problem and that will evaluate with propensity to obesity. As the level of obesity increases, the severity of the disease also increases [3,7,15,17,29]. NAFLD 3-100 % occurs with obesity. In that situation when patients are checked at ultrasound examination, fatty dystrophy of liver will found [7,30]. The scientific researches show that, NAFLD occurs 70% with 2nd type diabetes mellitus [2,24,30]. Thus, the progressive progression and prevalence of the disease is one of the current problems of clinical medicine due to the observation of the time when the working capacity of the population is preserved, close clinical signs are observed in the late stages of the disease [38,39]. There are many causes of development of the fatty steatosis of liver. Primary steatosis mostly, appears on the basis of obesity, hyperlip